Inari Medical (NARI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$1.96 (-3.80%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Inari Medical (NARI)
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Key Insights

Critical company metrics and information

  • Share Price

    $52.20

  • Market Cap

    $3.06 Billion

  • Total Outstanding Shares

    58.54 Million Shares

  • Total Employees

    1,300

  • Dividend

    No dividend

  • IPO Date

    May 22, 2020

  • SIC Description

    Surgical & Medical Instruments & Apparatus

  • Homepage

    https://www.inarimedical.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-14.49 Million
Net Cash Flow From Financing Activities$681000.00
Net Cash Flow From Financing Activities, Continuing$681000.00
Net Cash Flow From Operating Activities, Continuing$27.41 Million
Exchange Gains/Losses$125000.00
Net Cash Flow From Operating Activities$27.41 Million
Net Cash Flow From Investing Activities$-14.49 Million
Net Cash Flow, Continuing$12.23 Million
Net Cash Flow$12.36 Million

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Benefits Costs and Expenses$582.57 Million
Income Tax Expense/Benefit$21.96 Million
Research and Development$96.17 Million
Net Income/Loss$-57.05 Million
Net Income/Loss Attributable To Parent$-57.05 Million
Basic Average Shares$115.72 Million
Income/Loss From Continuing Operations After Tax$-57.05 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Revenues$547.47 Million
Preferred Stock Dividends And Other Adjustments$0.00
Cost Of Revenue$70.37 Million
Net Income/Loss Available To Common Stockholders, Basic$-57.05 Million
Diluted Average Shares$114.90 Million
Gross Profit$477.11 Million
Basic Earnings Per Share$0.98
Operating Income/Loss$-46.80 Million
Costs And Expenses$582.57 Million
Diluted Earnings Per Share$0.99
Operating Expenses$523.91 Million
Income/Loss From Continuing Operations Before Tax$-35.09 Million
Selling, General, and Administrative Expenses$406.99 Million

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Accounts Payable$16.38 Million
Noncurrent Liabilities$110.86 Million
Liabilities And Equity$672.93 Million
Wages$54.36 Million
Current Assets$249.35 Million
Other Current Liabilities$67.52 Million
Current Liabilities$138.26 Million
Inventory$49.36 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$199.99 Million
Equity$423.81 Million
Equity Attributable To Parent$423.81 Million
Assets$672.93 Million
Noncurrent Assets$423.58 Million
Other Non-current Assets$257.47 Million
Liabilities$249.12 Million
Intangible Assets$143.11 Million
Fixed Assets$23.00 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

â“’ 2024 Financhle. All Rights Reserved.